摘要
抗血管生成药物已成为肿瘤治疗的重要手段和研究热点。该类药物如贝伐单抗、舒尼替尼、索拉非尼、拉帕替尼等也被临床用于治疗乳腺癌,显示出一定疗效,同时也带来了一些问题和思考。
Anti-angiogenesis drug has become an important method and a hot research field for treating cancers. Drugs such as bevacizumab, sunitinib, sorafenib, lapatinib, achieved good clinical effect in treating breast cancers, but they also brought a lot of problems that need to be concerned.
出处
《肿瘤研究与临床》
CAS
2012年第2期73-75,83,共4页
Cancer Research and Clinic
关键词
乳腺肿瘤
血管生成抑制剂
Breast neoplasms
Angiogenesis inhibitors